Deflazacort for the treatment of Duchenne Dystrophy: A systematic review

被引：33

作者：

Craig Campbell

Pierre Jacob

机构：

[1] Division of Neurology, Children's Hosp. of Eastern Ontario, University of Ottawa, Ottawa, Ont.

来源：

BMC Neurology | / 3卷 / 1期

关键词：

Prednisone; Duchenne Dystrophy; Allocation Concealment; Duchenne Muscular Dystrophy; Deflazacort;

D O I：

10.1186/1471-2377-3-7

中图分类号：

学科分类号：

摘要：

Background: To complete a systematic review and meta-analysis based on the clinical question: Is Deflazacort (DFZ), a prednisolone derivative, an effective therapy for improving strength, with acceptable side effects, in children with Duchenne Dystrophy (DD)? Methods: MEDLINE, EMBASE, Current Contents, Dissertation Abstracts, Health Star, PsychINFO and Cochrane, were searched using the following inclusion criteria: 1) A randomized controlled trial comparing DFZ with placebo or another therapy; 2) Male participants age 2-18 years with DD; 3) Outcomes of (a) any form of strength or functional testing, or (b) any form of side effect. Results: Fifteen studies of potential relevance were identified, with five meeting the inclusion criteria. These five studies included 291 children and were published in English language journals between 1994 and 2000. Two studies compared DFZ versus placebo, two studies compared DFZ with prednisone and one study had both placebo and prednisone comparisions. Two large trials were identified that have not been published in article format. Due to the heterogeneity in outcome measures and the inconsistent reporting of summary statistics a meta-analytic approach could not be taken. Conclusions: Examining individual studies it appears that DFZ improves strength and functional outcomes compared to placebo, but it remains unclear if it has a benefit over prednisone on similar outcomes. Two trials found that DFZ causes less weight gain than prednisone. © 2003 Campbell and Jacob; licensee BioMed Central Ltd.

引用

共 33 条

[1]

Escolar D.M., Scacheri C.G., Pharmacologic and genetic therapy for childhood muscular dystrophies, Current Neurology and Neuroscience Reports, 1, pp. 168-174, (2001)

[2]

Griggs R.C., Moxley R.T., Mendell J.R., Fenichel G.M., Brooke M.H., Pestronk A., Miller J.P., Cwik V.A., Pandya S., Robison J., Et al., Duchenne dystrophy: Randomized, controlled trial of prednisone (18 months) and azathioprine (12 months), Neurology, 43, pp. 520-527, (1993)

[3]

Fenichel G.M., Mendell J.R., Moxley R.T., Brooke M.H., Griggs R.C., Miller J.P., Pestronk A., Robison J., King W., Signore L., Et al., A comparison of daily and alternate-day prednisone therapy in the treatment of Duchenne muscular dystrophy, Arch. Neurol., 48, pp. 575-579, (1991)

[4]

Griggs R.C., Moxley R.T., Mendell J.R., Fenichel G.M., Brooke M.H., Pestronk A., Miller J.P., Prednisone in Duchenne dystrophy a randomized controlled trial defining the time course and dose response, Arch. Neurol., 48, pp. 383-388, (1991)

[5]

Mendell J.R., Moxley R.T., Griggs R.C., Brooke M.H., Fenichel G.M., Miller J.P., King W., Signore L., Pandya S., Florence J., Et al., Randomized, double-blind six-month trial of prednisone in Duchenne's muscular dystrophy, N. Engl. J. Med., 320, pp. 1592-1597, (1989)

[6]

Biggar W.D., Gingras M., Fehlings D.L., Harris V.A., Steele C.A., Deflazacort treatment of Duchenne muscular dystrophy, J. Pediatr., 138, pp. 45-50, (2001)

[7]

(1992)

[8]

Emery A.E.H., The muscular dystrophies, Lancet, 359, pp. 687-695, (2002)

[9]

Moher D., Cook D.J., Eastwood S., Olkin I., Rennie D., Stroup D.F., Improving the quality of reports of meta-analyses of randomized controlled trials: The QUOROM statement, Lancet, 354, pp. 1896-1900, (1999)

[10]

Jadad A.R., Moore R.A., Carroll D., Jenkinson C., Reynolds J.M., Gavaghan D.J., McQuay H.J., Assessing the quality of reports of randomized clinical trials: Is blinding necessary?, Control Clin. Trials, 17, pp. 1-12, (1996)

← 1 2 3 4 →